Effects of Liraglutide on the Cognitive Function in Patients With Type 2 Diabetes Mellitus

NCT03707171 on ClinicalTrials.gov · last registry update 2019-07-10

A small phase 3 — 30 participants, against a typical 424. The sponsor logged completion for 1 February 2019. Primary outcome, as filed: Changes of cognitive function assessed by cognitive function scale after 12 weeks. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Third Military Medical University
Sponsor type: Other
Enrollment: 30
Started: 2018-10-01
Primary completion: 2019-02-01 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Changes of cognitive function assessed by cognitive function scale after 12 weeks.

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.